poisar

Stocks · News reference

Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CALC
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Delveinsight

    Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

    Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.

    GOSSRHHBYGSKCALCMLYS